New cholesterol drug

There are several new cholesterol-lowering drugs that have been approved by regulatory agencies in recent years. Here are a few examples:

1. Bempedoic acid (Nexletol): Approved by the FDA in 2019, bempedoic acid is an oral medication that works by inhibiting an enzyme called ATP citrate lyase, which is involved in the production of cholesterol in the liver. It is used in combination with statins to treat heterozygous familial hypercholesterolemia (HeFH) or mixed dyslipidemia.
2. Volanesorsen (Waylivra): Approved by the FDA in 2017, volanesorsen is an injectable medication that works by inhibiting the production of apolipoprotein C-III, a protein that can raise triglyceride levels. It is used to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder that causes extremely high triglyceride levels.
3. Lomitapide (Juxtapid): Approved by the FDA in 2013, lomitapide is an oral medication that works by inhibiting the production of cholesterol in the liver. It is used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high cholesterol levels.
4. Mipomersen (Kynamro): Approved by the FDA in 2013, mipomersen is an injectable medication that works by inhibiting the production of apolipoprotein B, a protein that is involved in the production of cholesterol in the liver. It is used to treat homozygous familial hypercholesterolemia (HoFH).
5. Evolocumab (Repatha): Approved by the FDA in 2015, evolocumab is an injectable medication that works by inhibiting the production of PCSK9, an enzyme that helps to regulate cholesterol levels in the liver. It is used to treat heterozygous familial hypercholesterolemia (HeFH) or mixed dyslipidemia.
6. Alirocumab (Praluent): Approved by the FDA in 2015, alirocumab is an injectable medication that works by inhibiting the production of PCSK9, an enzyme that helps to regulate cholesterol levels in the liver. It is used to treat heterozygous familial hypercholesterolemia (HeFH) or mixed dyslipidemia.
7. Anacetrapib (MDL 201,031): Approved by the FDA in 2017, anacetrapib is an oral medication that works by inhibiting the production of cholesterol in the liver. It is used to treat heterozygous familial hypercholesterolemia (HeFH) or mixed dyslipidemia.

These are just a few examples of new cholesterol-lowering drugs that have been approved in recent years. There are many other medications and treatments available to help manage cholesterol levels and reduce the risk of heart disease.